Takeda Drug Entyvio Beats AbbVie’s Humira in Ulcerative Colitis

Takeda Pharmaceutical Co. said its anti-inflammatory drug Entyvio was superior to AbbVie Inc.’s blockbuster injection Humira in a large head-to-head trial of patients with moderate to severe ulcerative colitis.

Takeda’s drug helped 31.3 percent of patients achieve disease remission after a year of treatment, compared with 22.5 percent of patients on Humira, according to data from a large trial presented March 9 at a medical conference in Copenhagen.

Key Insights

• The Takeda-sponsored trial could have implications for Humira, the world’s best-selling drug. The company said the trial is the first head-to-head test of the commonly used drugs in patients with ...